Leerink Partners analyst Ami Fadia maintained a Buy rating on Myovant Sciences (NYSE:MYOV) on Tuesday, setting a price target of $29, which is approximately 44.78% above the present share price of $20.03.
Fadia expects Myovant Sciences to post earnings per share (EPS) of -$0.73 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Myovant Sciences, with an average price target of $27.75.
The analysts price targets range from a high of $34 to a low of $20.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$64.14 million. The company's market cap is $1.77 billion.
According to TipRanks.com, Leerink Partners analyst Ami Fadia is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.9% and a 47.06% success rate.
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.